Cargando…

A phase II study of bryostatin 1 in metastatic malignant melanoma.

Bryostatin 1 is a protein kinase C partial agonist which has both antineoplastic and immune-stimulatory properties, including the induction of cytokine release and expansion of tumour-specific lymphocyte populations. In phase I studies, tumour responses have been observed in patients with malignant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Propper, D. J., Macaulay, V., O'Byrne, K. J., Braybrooke, J. P., Wilner, S. M., Ganesan, T. S., Talbot, D. C., Harris, A. L.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group\|1 1998
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063191/ https://www.ncbi.nlm.nih.gov/pubmed/9823975

Ejemplares similares

Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine
por: Propper, D J, et al.
Publicado: (2000)

Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply.
por: Thompson, C. H., et al.
Publicado: (1996)

Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer
por: O'Byrne, K J, et al.
Publicado: (1999)

Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer
por: Propper, D J, et al.
Publicado: (2000)

A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer
por: Madhusudan, S, et al.
Publicado: (2003)

Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha
por: Braybrooke, J P, et al.
Publicado: (2000)

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma
por: Blackhall, F H, et al.
Publicado: (2001)

Phase I study of the mitomycin C analogue BMS-181174.
por: Macaulay, V. M., et al.
Publicado: (1998)

A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.
por: Jayson, G. C., et al.
Publicado: (1995)

A phase I study of intravenous bryostatin 1 in patients with advanced cancer.
por: Prendiville, J., et al.
Publicado: (1993)

Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG‐N0377, Alliance)
por: Vera Aguilera, Jesus, et al.
Publicado: (2018)

Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer.
por: O'Byrne, K. J., et al.
Publicado: (1998)

Bryostatin analog: improving on Nature's design
por: Boger, Dale
Publicado: (2012)

Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer
por: Levitt, N C, et al.
Publicado: (2005)

Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma
por: Deplanque, G, et al.
Publicado: (2004)

Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents
por: Han, C, et al.
Publicado: (2003)

A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma
por: Clamp, A R, et al.
Publicado: (2003)

Phase II trial of imatinib mesylate in patients with metastatic melanoma
por: Kim, K B, et al.
Publicado: (2008)

Bryostatin Effects on Cognitive Function and PKCɛ in Alzheimer’s Disease Phase IIa and Expanded Access Trials
por: Nelson, Thomas J., et al.
Publicado: (2017)

A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study)
por: Stebbing, J, et al.
Publicado: (2008)

Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors
por: Thijsen, S F T, et al.
Publicado: (1999)

Munc13 Is a Molecular Target of Bryostatin 1
por: Blanco, Francisco A., et al.
Publicado: (2019)

Bryostatin-1: a promising compound for neurological disorders
por: Tian, Zhen, et al.
Publicado: (2023)

Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma
por: DeConti, R C, et al.
Publicado: (2010)

Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents
por: Marsden, Matthew D., et al.
Publicado: (2018)

Lymphatic density and metastatic spread in human malignant melanoma
por: Shields, J D, et al.
Publicado: (2004)

Phorbol ester and bryostatin effects on growth and the expression of oestrogen responsive and TGF-beta 1 genes in breast tumour cells.
por: Nutt, J. E., et al.
Publicado: (1991)

Chronic bryostatin-1 rescues autistic and cognitive phenotypes in the fragile X mice
por: Cogram, Patricia, et al.
Publicado: (2020)

A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma
por: Hasanov, Merve, et al.
Publicado: (2020)

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer’s Disease
por: Farlow, Martin R., et al.
Publicado: (2019)

Establishment of a murine leukaemia cell line resistant to the growth-inhibitory effect of bryostatin 1.
por: Prendiville, J., et al.
Publicado: (1994)

A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates
por: Ott, Patrick A., et al.
Publicado: (2010)

Designed, Synthetically Accessible Bryostatin Analogues Potently Induce Activation of Latent HIV Reservoirs in vitro
por: DeChristopher, Brian A., et al.
Publicado: (2012)

Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
por: Pectasides, D., et al.
Publicado: (1989)

Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma.
por: Kerr, D. J., et al.
Publicado: (1989)

Chronic immune activation and inflammation as the cause of malignancy
por: O'Byrne, K J, et al.
Publicado: (2001)

Simplified Bryostatin Analogues Protect Cells from Chikungunya Virus-Induced Cell Death
por: Staveness, Daryl, et al.
Publicado: (2016)

Neristatin 1 Provides Critical Insight into Bryostatin 1 Structure–Function Relationships
por: Kedei, Noemi, et al.
Publicado: (2015)

PKC modulator bryostatin-1 therapeutically targets CNS innate immunity to attenuate neuroinflammation and promote remyelination
por: Gharibani, Payam, et al.
Publicado: (2023)

Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma
por: Fruehauf, John P., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_182cqbhgdr0j1olf6j374giauo